DRNA Dicerna Pharmaceuticals Inc.

19.81
+1.91  (+11%)
Previous Close 17.9
Open 18.51
Price To Book 9.62
Market Cap 1,460,999,723
Shares 73,750,617
Volume 507,850
Short Ratio
Av. Daily Volume 725,314
Stock charts supplied by TradingView

NewsSee all news

  1. Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the

  2. Dicerna Provides Initial Observations From PHYOX™3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria and an Update on Data Presentation Plan

    — Preliminary Interim Data Show Normalization or Near-Normalization of Oxalate Levels in First Subset of Four Patients — — Nedosiran Multidose Data to Be Presented at OxalEurope Meeting Now Rescheduled to June 16,

  3. Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic

    Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of ribonucleic acid interference (RNAi) therapies, today provided an overview of its response to the COVID-19 pandemic and an

  4. Dicerna Receives Orphan Drug Designation From U.S. Food and Drug Administration for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency

    Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the U.S. Food and Drug

  5. Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Development discontinued September 2016.
DCR-MYC
Hepatocellular carcinoma (HCC) - cancer
Phase 2/3 enrolment originally to be completed 2Q 2020 has been delayed due to COVID-19. Updated timeline due at a later date.
DCR-PHXC - PHYOX2
Primary hyperoxaluria (PH)
Phase 1 data due August 2020.
RG6346 (DCR-HBVS)
Hepatitis B virus (HBV)
Phase 1/2 pause in enrolment at higher doses is likely due to COVID-19.
DCR-A1AT
Alpha-1 antitrypsin (A1AT) deficiency-associated liver disease
Phase 1 multi-dose data presented March 31, 2020. More detailed data due June 2020.
DCR-PHXC - PHYOX3
Primary hyperoxaluria (PH)

Latest News

  1. Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the

  2. Dicerna Provides Initial Observations From PHYOX™3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria and an Update on Data Presentation Plan

    — Preliminary Interim Data Show Normalization or Near-Normalization of Oxalate Levels in First Subset of Four Patients — — Nedosiran Multidose Data to Be Presented at OxalEurope Meeting Now Rescheduled to June 16,

  3. Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic

    Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of ribonucleic acid interference (RNAi) therapies, today provided an overview of its response to the COVID-19 pandemic and an

  4. Dicerna Receives Orphan Drug Designation From U.S. Food and Drug Administration for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency

    Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the U.S. Food and Drug

  5. Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the

  6. Dicerna™ Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    — Company Achieves Multiple Clinical and Corporate Development Milestones in 2019, Advancing Core Pipeline Candidates; Expanding and Progressing Existing Collaborative Programs; and Establishing New, High-Value

  7. Dicerna™ to Report Fourth Quarter and Full Year 2019 Financial Results on Feb. 27, 2020

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2019

  8. Dicerna™ to Present at Upcoming Investor Conferences

    Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive

  9. Dicerna™ Appoints Stephen Doberstein, Ph.D., to Board of Directors

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Stephen Doberstein,

  10. Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the

  11. Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics, today announced that the Compensation Committee

  12. Dicerna™ Announces Closing of Agreement With Novo Nordisk for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the discovery and

  13. Dicerna™ Announces Closing of Worldwide Collaboration and Licensing Agreement With Roche for Treatments for Chronic Hepatitis B Virus Infection

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the successful closing of the research

  14. Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the European Commission (EC) has

  15. Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™

    – Option Exercise Triggers $20 Million Payment to Dicerna – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that Alexion has exercised its option for

  16. Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid (RNA) interference (RNAi) therapeutics, today announced that the Compensation Committee

  17. Dicerna™ to Present at Evercore ISI 2nd Annual HealthCONx Conference

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D.,

  18. Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

    – Collaboration to Explore Liver Cell Targets Using Dicerna's GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates – – Each Company to Retain Rights to Co-Develop

  19. Dicerna™ to Present at the Stifel 2019 Healthcare Conference

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D.,

  20. Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress

    — Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX™2 Pivotal Clinical Trial — — Announced Collaboration Agreement With Roche for Development of DCR-HBVS Including Option to Co-Fund

  21. Dicerna™ to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its

  22. Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the

  23. Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

    – Roche to gain worldwide license to Dicerna's novel RNAi therapy currently in Phase 1 – – Dicerna to receive $200 million up front plus up to $1.47 billion in potential milestone payments related to DCR-HBVS – –

  24. Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the

  25. Dicerna™ to Present at Two Upcoming Investor Conferences

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that management will present at two

  26. Dicerna™ Appoints Patrick Gray to Board of Directors to Support Continued Growth

    Company Announces Retirement of Board of Director Veteran Dennis Langer Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today

  27. Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the

  28. Dicerna™ to Present at H.C. Wainwright 21st Annual Global Investment Conference

    Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D.,